Advice
Following SMC collaboration with NICE on TA971: remdesivir and tixagevimab plus cilgavimab for treating COVID-19:
tixagevimab and cilgavimab (Evusheld®) is not recommended within NHSScotland.
Indication under review: treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.
Download detailed advice230KB (PDF)
Medicine details
- Medicine name:
- Tixagevimab and cilgavimab (Evusheld)
- SMC ID:
- SMC2558
- Indication:
Treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Infections
- Submission type
- Collaboration
- Status
- Not recommended
- Date advice published
- 08 May 2024